- Author
-
J. de Bruijne
- Title
- Direct-acting antiviral therapy for chronic hepatitis C
- Supervisors
-
U. Beuers
P.L.M. Jansen - Co-supervisors
-
H.W. Reesink
R. Molenkamp - Award date
- 21 September 2012
- Number of pages
- 289
- ISBN
- 9789090267227
- Document type
- PhD thesis
- Faculty
- Faculty of Medicine (AMC-UvA)
- Abstract
-
Hepatitis C virus (HCV) infection was discovered in the late 1980s. Since then, tremendous progress has been made in understanding the pathophysiology of HCV infection together with the development of improved therapies for patients with chronic hepatitis C.
The main focus of this thesis was to improve our understanding of new treatment strategies for chronic hepatitis C. Several direct-acting antivirals were investigated in multiple in vitro and in vivo studies. This thesis gives more insight into the pathogenesis of chronic HCV infection, its epidemiology, development of innovative treatments and upcoming viral resistance during therapy with direct-acting antivirals. The results of this thesis contribute to the impressive treatment progress, which will ultimately improve the prognosis of chronic hepatitis C patients. - Note
- Research conducted at: Universiteit van Amsterdam
- Persistent Identifier
- https://hdl.handle.net/11245/1.385725
- Downloads
-
Thesis
Front cover
Title pages
Table of contents
Chapter 1: General introduction
Chapter 2: Safety and antiviral activity of JTK-652: a novel hepatitis C virus infection inhibitor
Chapter 3: Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
Chapter 4: Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor
Chapter 5: Pharmacokinetics and antiviral activity of PHX1766, a novel hepatitis C virus protease inhibitor using an accelerated phase 1 study design
Chapter 6: First-in-human pharmacokinetics and antiviral activity of IDX375, a novel non-nucleoside hepatitis C virus polymerase inhibitor
Chapter 7: Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles
Chapter 8: Long-term follow-up of genotypic changes in patients treated with narlaprevir
Chapter 9: Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir
Chapter 10: TMC435 combination treatment in hepatitis C virus genotype 1-infected patients previously exposed to TMC435
Chapter 11: Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment
Chapter 12: Upregulation of CXCR3+ expression on CD8+ T cells due to the pervasive influence of chronic hepatitis B and C virus infection
Chapter 13: Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV
Chapter 14: General discussion and perspectives
Summary
Samenvatting voor niet ingewijden
Dankwoord
List of publications
Colour figures
About the author / Statements
Back cover
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.